Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy A Yap

Showing results (211-220 of 260) with videos related to

Pageof 26
Sort By:
Journal of the National Cancer Institute|December 19, 2018
Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in OncologyBrian P Hobbs, Pedro C Barata, Yada Kanjanapan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2013
First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studiesTimothy A Yap, Hendrik-Tobias Arkenau, D Ross Camidge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2025
Genomic and epigenomic ctDNA profiling in liquid biopsies from heavily pre-treated patients with DNA damage response-deficient tumorsIan M Silverman, Joseph D Schonoft, Benjamin Herzberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2024
First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced MalignanciesNehal J Lakhani, Kyriakos P Papadopoulos, Melissa Lynne Johnson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2024
Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract CancerTimothy P DiPeri, Kurt W Evans, Stephen Scott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2022
Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)Justin T Moyers, Roberto Carmagnani Pestana, Jason Roszik, et al.
Clinical Genitourinary Cancer|August 7, 2021
Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy TrialsOmar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.
Journal of Immunotherapy and Precision Oncology|February 8, 2023
Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical CancerJi Son, Heather Y Lin, Siqing Fu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2015
Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug AdministrationJean Sebastien Frenel, Suzanne Carreira, Jane Goodall, et al.
Journal of Immunotherapy and Precision Oncology|February 17, 2025
Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I TrialMirella Nardo, Mohamed A Gouda, Matthew J Reilley, et al.
Pageof 26

Showing results (211-220 of 260) with videos related to

Sort By:
Pageof 26
Journal of the National Cancer Institute|December 19, 2018
Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in OncologyBrian P Hobbs, Pedro C Barata, Yada Kanjanapan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2013
First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studiesTimothy A Yap, Hendrik-Tobias Arkenau, D Ross Camidge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2025
Genomic and epigenomic ctDNA profiling in liquid biopsies from heavily pre-treated patients with DNA damage response-deficient tumorsIan M Silverman, Joseph D Schonoft, Benjamin Herzberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2024
First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced MalignanciesNehal J Lakhani, Kyriakos P Papadopoulos, Melissa Lynne Johnson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2024
Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract CancerTimothy P DiPeri, Kurt W Evans, Stephen Scott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2022
Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)Justin T Moyers, Roberto Carmagnani Pestana, Jason Roszik, et al.
Clinical Genitourinary Cancer|August 7, 2021
Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy TrialsOmar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.
Journal of Immunotherapy and Precision Oncology|February 8, 2023
Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical CancerJi Son, Heather Y Lin, Siqing Fu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2015
Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug AdministrationJean Sebastien Frenel, Suzanne Carreira, Jane Goodall, et al.
Journal of Immunotherapy and Precision Oncology|February 17, 2025
Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I TrialMirella Nardo, Mohamed A Gouda, Matthew J Reilley, et al.
Pageof 26